Paul Sekhri
Head, Biotech Ops Group, TPG Biotech/TPG Growth
Prior to joining TPG Biotech in January 2009 as Head, Biotech Ops Group, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Prior to ARIAD, Mr. Sekhri joined the Sprout Group (now New Leaf Ventures), where he was a Partner for Healthcare Technology investments.
Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Prior to this, Mr. Sekhri developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis’ pipeline.
Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology. Mr. Sekhri is currently a Member of the Board of Directors of Affectis Pharmaceuticals, APT Pharmaceuticals, ARYx Therapeutics, KAI Pharmaceuticals, IMS Health, Intercept Pharmaceuticals, Macrogenics, and Moksha8.
Additionally he is on the Board of Directors of the Cancer Research Institute (CRI), Ontario Institute for Cancer Research (OICR) Board Subcommittee on Commercialization, and the BioExec Institute, Inc. Mr. Sekhri is also an Advisor to the Brookings Global Health Financing Initiative, is an LES M&A Committee member, and was recently elected to the Board of Trustees of Carnegie Hall.